Document Detail

Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with placebo in patients with congestive heart failure.
MedLine Citation:
PMID:  3921279     Owner:  NLM     Status:  MEDLINE    
The dose requirements and duration of effect of transdermal nitroglycerin in patients with heart failure are not clearly established. In a first series of eight patients with chronic heart failure we gave transdermal nitroglycerin in incremental doses until pulmonary capillary wedge pressure fell at least 30% within 4 hr in three consecutive patients. Thus we found that a single dose of 60 mg/24 hr (120 cm2) was the minimal effective dose. Transdermal nitroglycerin or placebo was then given as a single application of 60 mg/24 hr in random double-blind fashion to 15 additional patients with heart failure (eight received transdermal nitroglycerin and seven received placebo), and hemodynamics were monitored for up to 24 hr. After administration of transdermal nitroglycerin, the control pulmonary capillary wedge pressure of 22 +/- 7 mm Hg fell by 6 +/- 6 mm Hg at 2 hr (p less than .05) and reached maximal reduction of 8 +/- 6 mm Hg (p less than .01) at 4 hr. The reduction in wedge pressure remained significant through 12 hr but was no longer statistically significant by 18 hr after administration of the drug. Transdermal nitroglycerin also significantly reduced pulmonary arterial and right atrial pressures as well as pulmonary vascular resistance from 4 through 12 hr but did not affect systemic hemodynamics. No significant hemodynamic changes occurred after administration of placebo. Thus transdermal nitroglycerin is an effective vasodilator in patients with heart failure, but a dose of at least 60 mg/24 hr is needed. Even with this dose, hemodynamic effects do not last beyond 18 hr, suggesting altered absorption or development of tolerance.
R A Jordan; L Seith; D A Henry; M M Wilen; J A Franciosa
Related Documents :
3343939 - Assessing the deformation of pulmonary capillaries produced by ventilation.
14605079 - Clinical and exercise test determinants of survival after cardiac transplantation.
18380759 - Noninvasive methods for determining pulmonary vascular function in children with pulmon...
1153409 - Comparison of the effects of prostaglandins f1alpha, f2alpha, f1beta, and f2beta on the...
17894029 - Pulmonary blood volume in rheumatic heart disease and its alteration by isoproterenol.
8239149 - Endothelin-1 in adult respiratory distress syndrome.
1628689 - Further studies of the pressure from the tongue on the teeth in young adults.
13932039 - Electrophysiology of an insect heart.
18701619 - Otolithic activation on visceral circulation in humans: effect of aging.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  71     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1985 May 
Date Detail:
Created Date:  1985-05-30     Completed Date:  1985-05-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  980-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Blood Pressure / drug effects
Dose-Response Relationship, Drug
Heart Failure / drug therapy,  physiopathology*
Heart Rate / drug effects
Middle Aged
Nitroglycerin / administration & dosage*
Placebos / administration & dosage*
Pulmonary Wedge Pressure
Stroke Volume / drug effects
Vascular Resistance / drug effects
Reg. No./Substance:
0/Placebos; 55-63-0/Nitroglycerin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Superiority of combined diltiazem and propranolol therapy for angina pectoris.
Next Document:  Application of fluorescence polarization to the determination of urinary lysozyme activity.